Health technology public relations operates under constraints that most PR never meets. In other sectors, an exaggerated claim costs credibility when it is found out. In health, an exaggerated claim can cost a patient their safety, a clinician their licence to trust the next product, and a company its permission to operate — because the claims concern bodies, the audiences include people who can check them professionally, and regulators can act on them. This article explains what the discipline actually requires: how claims in health are graded by evidence and regulatory status, where the hard boundaries sit, and what public relations can honestly contribute.

The title of this article, like many in the field, speaks of driving adoption and awareness. The body of it will be more careful, because the honest version is narrower and more demanding: health technology public relations supplies accurate, checkable information to the people who decide. Adoption follows evidence, authorisation and experience. It is not a communications deliverable, and treating it as one is how health PR gets into trouble.

Why Health Is Different

Three properties separate health technology from the rest of the technology market. First, the subject matter is the body: a claim about a device, a diagnostic or a digital therapy is a claim about what will happen to a person’s health, and the distance between a misunderstood claim and a harmed patient is short. Second, the audience is expert and empowered. Clinicians evaluate evidence for a living and can detect an inflated claim at a glance; procurement and clinical-governance processes exist precisely to slow adoption until the evidence is examined. Third, the sector is regulated in ways that reach directly into communications: what may be claimed about a health product is, in large part, determined by what has been demonstrated and authorised, not by what a marketing team would like to say.

Together, these properties invert the usual PR instincts. Speed matters less than accuracy. Reach matters less than the right audience understanding the claim correctly. And the penalty structure is asymmetric: a reputation built over years of careful communication can be spent in a single news cycle by one claim that outran its evidence. Good health technology public relations is therefore not ordinary PR with medical vocabulary. It is a discipline whose first skill is knowing what may not be said.

The Claims Hierarchy: Studied, Authorised, Investigational

Every health technology claim sits somewhere in a hierarchy, and the communicator’s first job is to know where. PR copy blurs the levels constantly — a product described in the language of the level above the one it has reached. Keeping the levels separate, in every sentence, is the core craft of this field.

What Has Been Studied

At the first level, something has been studied: evaluated in a trial, a pilot or a published analysis, with results that can be read and questioned. A claim at this level may report what the study found, in the population studied, with the limitations stated. It may not generalise beyond the study — to other patients, other settings or longer timeframes than the evidence covers. The discipline is in the qualifiers, and the qualifiers are not fine print: for a clinical audience, they are the claim.

What Has Been Authorised

At the second level, a regulator has authorised or cleared the product for specified uses. Authorisation is precise: it covers defined indications, defined populations and defined claims, and communication that wanders outside them is not enthusiasm, it is a compliance failure with legal and safety consequences. The communicator’s duty is to work from the authorised wording, not to paraphrase it into something broader. Where the authorised claim is narrower than the marketing ambition, the authorised claim wins, every time, in every channel.

What Is Still Investigational

At the third level, the technology is still being investigated: promising, perhaps, but unproven and unauthorised. Communication at this level may describe the research, its stage and its questions. It may not borrow the grammar of the levels above — no language of outcomes, benefits or transformation for something whose effects are precisely what the investigation exists to establish. The commonest failure in health technology PR is investigational work announced in authorised language, and it is a failure of honesty before it is a failure of compliance, because the audience cannot tell the difference until someone is harmed or disappointed.

Privacy: A Hard Boundary, Not a Preference

Health information is among the most sensitive categories of personal data, and it is protected accordingly: health privacy law, in its various national forms, treats patient information as something held under strict duties, and medicines and devices regulators treat data handling as part of a product’s safety profile. For the communicator this has practical consequences that admit no exceptions. No patient’s information appears in any communication — a case story, a photograph, a screenshot, a dataset in a press pack — without a lawful basis and genuine, informed consent, handled as a legal and ethical process rather than a signature collected for marketing convenience.

The boundary also governs how data claims are made. A health technology company holds information whose sensitivity its own marketing can easily understate; describing data practices accurately, including their limits, is part of the claims discipline, not a legal footnote to it. This article describes the boundary at a general level deliberately: the specifics belong to qualified legal advice in the relevant jurisdiction, and any communications team working near patient data should be operating under exactly that advice, not under a blog post’s summary of it.

Testimonials and Endorsements, Under Constraint

The standard advice in this field — the original version of this article included — is to build credibility through expert endorsements and patient testimonials. In health, that advice needs its missing half. A patient’s story may describe their experience: what using the technology was like, what the care pathway felt like, what they would tell someone in their position. What it may not do is carry an efficacy claim. A first-person account of improvement, selected and published by the company, functions as an implied claim that the product works — a claim the evidence, not the anecdote, is required to support. One person’s outcome, however genuine, is not data about what the next patient should expect, and presenting it as though it were is the testimonial’s quiet dishonesty.

Expert endorsement is bounded the same way. A clinician’s name lends a claim exactly the weight of the evidence behind it and no more; an endorsement that outruns the study or the authorisation borrows authority the profession will eventually reclaim, publicly. The honest use of both devices exists — experience described as experience, expertise applied to what the evidence shows — and in a sector where audiences are trained to check, the constrained version is also the only version that survives checking.

Plain Language as a Safety Discipline

In most sectors, jargon is a style fault. In health, it is closer to a safety hazard. The audiences for health technology communication include patients and carers reading under stress, often with limited health literacy, making decisions about their own bodies. An instruction misunderstood, a risk understated because it was wrapped in technical vocabulary, a benefit overstated because a qualifier was trimmed for readability — each is a potential harm with a communications cause. Plain language in this field is therefore not a preference for simplicity. It is the discipline of writing so that the least expert reader the material will reach can still act on it correctly.

Misinformation compounds the duty. Health attracts confident falsehood like no other subject, and a health technology company’s communications exist in an environment where its claims will be screenshot, summarised and argued with. The practical defences are unglamorous: claims stated once, precisely, in words that survive quotation; corrections issued in the same channels and at the same prominence as the original error; and no reliance on the audience’s inability to check. In health, the audience can check, and increasingly does.

Crisis in Health: Accuracy Before Speed

Health technology crises are of two kinds, and both are about safety before they are about reputation: a product-safety event, in which something the company made or supplied may have harmed or may harm patients; and a data event, in which protected health information has been exposed. In both, the ordering discipline is the same and it reverses the usual crisis instinct. Speed of accuracy comes before speed of response. A fast statement that turns out to be wrong about a safety question does more damage — to patients first, and then to the company — than a slower statement that is right, and the interval must be spent verifying, with regulators and clinical leads inside the process, not announcing around them.

What the company owes in such an event is a public record that corrects itself in public: what is known, what is not yet known, what affected people should do, and updates at the times promised, including updates that say nothing has changed. The reputational outcome is a by-product of that conduct, and in health more than anywhere, attempting to manage the by-product directly — reassurance ahead of verification — is read by every professional audience as the confession it usually is.

What PR Actually Contributes

Stripped of the outcome language, the contribution is real and worth stating precisely. Health technology public relations puts accurate, level-correct information in front of the audiences who decide — clinicians, service managers, patients, journalists who cover the sector — in language each of them can act on. It keeps the public record of a product’s claims aligned with the evidence and the authorisation as both evolve. It maintains the channels through which corrections, safety information and updates actually reach people. The instinct is the same substantiation discipline applied to ESG communications — a claim is only as good as what stands behind it — translated into a sector where the thing standing behind the claim is clinical evidence and regulatory status, and where the cost of a gap is measured in safety, not embarrassment.

Education sits inside that contribution, properly understood. Explaining a genuinely novel technology to the people who must evaluate it — how it works, what it is for, what it is not for — is substantive work, and much of health technology PR is exactly this. What it is not is persuasion of the unconvinced by volume. In a market of expert gatekeepers, the educational artefact that respects the claims hierarchy will outperform the campaign that ignores it, because the gatekeepers’ professional duty is to find the gap, and there is either a gap or there is not.

Measurement, Honestly

Measurement in this field must be as disciplined as the claims. Adoption of a health technology is a clinical and operational outcome: it follows trials, authorisations, procurement, training and the experience of the first services to use it. It is not a communications metric, and a PR programme that reports adoption as its own result is claiming credit for the work of evidence and implementation. What communications can legitimately measure is its own layer: whether the deciding audiences encountered the information, whether they understood the claims at the correct level — a misunderstanding rate is a more honest health metric than a reach figure — and whether the public record stayed accurate. Report those, and let adoption belong to the people whose work it is.

Frequently Asked Questions

Can a Health Technology Be Promoted Before It Is Authorised?

Its research can be communicated; the product’s benefits cannot. Before authorisation, honest communication describes the investigation — what is being studied, at what stage, to answer what question — in investigational language. The moment the copy borrows the grammar of established benefit, it has made a claim the regulatory process exists to test, and both regulators and clinical audiences will treat it accordingly.

Are Patient Stories Off Limits Entirely?

No — they are bounded, not banned. With genuine consent and a lawful basis, a patient may describe their experience of care and of using a technology. The story must be presented as one person’s experience, may not be selected or edited into an implied promise of results, and may not substitute for the evidence wherever a reader must judge whether the technology works. Experience as experience: permitted and often valuable. Experience as data: not permitted.

Does Every Health Technology Release Need Legal or Regulatory Review?

Anything carrying a product claim should pass review by the people accountable for regulatory compliance before it is published — in this sector that is standard practice, not caution theatre, because the claim’s permissibility is a regulatory fact, not a copy preference. Communications teams should treat review as part of the drafting process, and treat this article the same way: a description of the discipline at a general level, never a substitute for jurisdiction-specific advice.

Conclusion

Health technology public relations is where the ordinary discipline of honest PR meets its strictest test. The claims concern bodies; the audiences can check; the regulators can act; and the hierarchy — studied, authorised, investigational — grades every sentence whether the writer respects it or not. Practised properly, the work is neither image management nor adoption engineering. It is the steady supply of accurate, level-correct information about technologies on which people’s health depends, inside boundaries set by evidence, authorisation and privacy law. In a sector built on trust that must be earned from experts, that restraint is not the limit of the discipline. It is the discipline.